Apart from obesity drug Qsymia,
) portfolio consists of another approved product, Stendra (trade
name: Spedra in Europe), for erectile dysfunction (ED). Stendra,
a phosphodiesterase type 5 (PDE5) inhibitor, received marketing
approval in the U.S. in Apr 2012 and in the EU in Jun 2013.
VIVUS has entered into a license and commercialization agreement
with Menarini. As per the terms of the agreement, Menarini will
get the rights to Stendra in more than 40 European countries,
apart from Australia and New Zealand.
VIVUS has entered into an agreement for Stendra with
Auxilium Pharmaceuticals, Inc.
As per the terms of the agreement, Auxilium will get the rights
to Stendra in the U.S. and Canada. In exchange VIVUS will get an
upfront payment, milestone and other payments totaling
approximately $300 million, depending upon certain pre-specified
VIVUS and Auxilium also entered into a supply agreement for
Stendra, according to which VIVUS will supply the product to the
The partnership on Stendra will not only boost VIVUS' balance
sheet but also go a long way in removing uncertainties related to
the drug's launch in the U.S. scheduled later this year.
In Jul 2013, VIVUS had announced encouraging data from a
multi-center, placebo-controlled study (TA-501) evaluating the
efficacy of Stendra in men suffering from ED.
The study enrolled 440 patients with mild-to-severe ED with or
without diabetes. Data from the study revealed that on an average
Stendra was effective after 10 minutes and 12 minutes of taking
the 200 mg and 100 mg formulation of the drug, respectively.
According to the company, ED therapies recorded combined sales of
over $2.9 billion in 2012 in the U.S. The ED market is expected
to grow further in the coming years.
Currently approved PDE5 inhibitors including Viagra and Cialis
are recommended for ingestion one to two hours prior to sexual
activity or daily. We believe Stendra's fast action could help
the drug gain share.
VIVUS currently carries a Zacks Rank #3 (Hold). Currently,
Isis Pharmaceuticals, Inc.
) look more attractive with a Zacks Rank #1 (Strong Buy).
AUXILIUM PHARMA (AUXL): Free Stock Analysis
ISIS PHARMACEUT (ISIS): Free Stock Analysis
ROCHE HLDG LTD (RHHBY): Get Free Report
VIVUS INC (VVUS): Free Stock Analysis Report
To read this article on Zacks.com click here.